Shibuya chooses ADVA to deliver encrypted services to Nordic banks
16.2.2023 11:00:00 EET | Business Wire | Press release
ADVA (FSE: ADV) today announced that Shibuya is deploying its open optical technology to deliver secure managed services to leading banks across the Nordics and Baltics. The new network features robust optical encryption cards from Adva Network Security for critical data protection. Shibuya, a leading Swedish IT service provider and ADVA’s long-term Select partner, is using the solution to offer highly available connectivity with end-to-end data protection.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230215005611/en/
ADVA’s technology is helping banks securely transport mission-critical data throughout the Nordic and Baltic regions. (Photo: Business Wire)
“For our financial customers, security couldn’t be more crucial. That’s why we’re ensuring that our managed services protect data in motion with the most robust defense available. At Shibuya, we specialize in delivering secure and sustainable IT environments, and ADVA’s solutions are a perfect fit,” said Jessica Liljefors, business area manager at ShibuyaCare, Shibuya. “Adva Network Security‘s encryption technology and the unique experience of its team help us deliver the strongest possible protection and offer complete peace of mind to our banking clients and their customers. Combined with our extensive cybersecurity measures, local data centers near the customers and 24/7 IT support, we can provide the high-end services demanded by the financial sector.”
The new solution safeguards mission-critical financial traffic using ConnectGuard™ Optical encryption technology provided by Adva Network Security. The technology protects data in-flight to the strictest regulatory requirements with minimal impact on throughput. Part of the new infrastructure is built on the ADVA FSP 3000 TeraFlex™ platform, which uses ultra-flexible modulation with fractional QAM. This supports 600Gbit/s streams while ensuring the lowest possible cost per bit. ADVA’s technology also supports the latest generations of low-latency Fibre Channel, empowering financial network operators to keep up with the requirements of new server and storage technologies – a key consideration for Shibuya and some of its enterprise customers.
“The reputation of today’s financial institutions is built on trust and confidence. By enabling banking customers to harness our TeraFlex™ terminal and enterprise cards, Shibuya is ensuring that Nordic financial enterprises can protect the integrity of highly sensitive data wherever it happens to be in the network. What’s more, our technology delivers the highest levels of performance while also reducing cost per bit,” commented Hartmut Müller-Leitloff, SVP of sales EMEA at ADVA. “And for major banks, being able to utilize the best available storage area network protocols is also key for meeting new business continuity needs and staying operational in the face of any disruption.”
About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com.
About Shibuya
Shibuya creates secure and sustainable IT environments for a digital Sweden. The company is one of the country’s premier operators in business-critical IT and delivers services in, among other things, data center infrastructure and IT operation, hybrid cloud solutions, cyber security, 24/7 IT service and support, communication, application operations and third-party services. Shibuya has strategic partnerships with leading manufacturers and reference solutions with several of the Nordics’ most demanding IT operations in both the private and public sectors. The company is certified according to ISO 14001, 9001 and 27001 standards and is part of the Pulsen Group. www.shibuya.se
Published by:
ADVA Optical Networking SE, Munich, Germany
www.adva.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230215005611/en/
Contact information
For press:
Gareth Spence
t +44 1904 699 358
public-relations@adva.com
For investors:
Stephan Rettenberger
t +49 89 890 665 854
investor-relations@adva.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Backed by Investments Exceeding $1 Billion, PCI Pharma Services Announces Major Expansion of US Sterile Fill-Finish and Drug-Device Delivery Combination Capabilities27.4.2026 17:00:00 EEST | Press release
PCI Pharma Services (“PCI”) – a world-leading integrated global contract development and manufacturing organization (CDMO) focused on innovative biologic and small molecule therapies – announced a series of major infrastructure investments that substantially deepen its sterile fill-finish and advanced drug delivery capabilities. As pharma manufacturers and their development partners increasingly prioritize US supply chain resilience, PCI’s latest investments come as part of a broader commitment exceeding $1 billion across the CDMO’s US and European operations, reinforcing its ability to provide seamless support for drug product development and manufacturing, clinical trial supply and drug-device combination assembly from clinical stages through commercial launch – all underpinned by global capacity, technical expertise, deep scientific knowledge, and an industry-leading quality and regulatory track record. This press release features multimedia. View the full release here: https://www.
Pure Lithium Appoints Renowned Battery Expert Dr. Yuan Gao to Board of Directors27.4.2026 16:53:00 EEST | Press release
Pure Lithium Corporation, a vertically integrated lithium metal battery technology company, is pleased to announce that world-renowned inventor and battery expert Dr. Yuan Gao has joined the company’s Board of Directors. Dr. Gao has been an invaluable member of Pure Lithium’s Scientific Advisory Board since October of 2023. "We are thrilled to have Dr. Gao join our board as we focus on rapidly scaling our technology in the most capital efficient manner possible,” said Pure Lithium Founder, Chairman and CEO Emilie Bodoin. “Dr. Gao is a brilliant scientist who also has deep commercial expertise, a rare combination. He is also unique in the industry because his experience spans the entire battery materials value chain, including all of Pure Lithium’s verticals. His insights over the years have been critical in advancing our technology, and his experience as a director of public companies will strengthen our board.” Dr. Gao commented: “I am thrilled to join the board of Pure Lithium Corpor
Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 202627.4.2026 16:00:00 EEST | Press release
Boomi, the data activation company, today announced Boomi World 2026, its premier annual user conference, taking place May 11 - 14, 2026 in Chicago, IL. The event will bring together customers, partners, and industry leaders from around the world to explore how data activation is transforming the enterprise and accelerating the path to AI-driven outcomes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427600340/en/ Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 2026 Boomi World 2026 will spotlight data activation — bringing data to life to power AI, analytics, and intelligent automation. Attendees will gain firsthand insights into how the Boomi Enterprise Platform enables businesses to unify data, streamline operations, and innovate faster in an increasingly agentic world. “Data is only valuable when it’s activated,” said Steve Lucas, Chairman and CEO, Boomi. “At Boomi World 2026, we
Axinn Appoints Rachael Philbin as Chief Innovation Officer27.4.2026 16:00:00 EEST | Press release
Axinn, Veltrop & Harkrider LLP today announced the appointment of Rachael Philbin as Chief Innovation Officer, reinforcing the firm’s continued investment in advanced solutions and technology for legal services delivery. Philbin joins from Proskauer Rose LLP, where she served as Innovation & Transformation Officer. Based in Axinn's New York office, she will lead the firm’s AI and legal technology initiatives as well as knowledge management efforts, accelerating adoption and integration across its antitrust, intellectual property, and litigation practices. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427277725/en/ Rachael Philbin joins Axinn, Veltrop & Harkrider LLP as Chief Innovation Officer. “As Axinn continues to grow, we are making deliberate investments in the capabilities that enable our lawyers to deliver service and results at the highest level in our clients’ complex matters,” said Jeny Maier, managing partner
Taiho Oncology, Taiho Pharmaceutical and Araris Biotech AG Advance ADC ARC-02 into Phase 1 Clinical Development27.4.2026 16:00:00 EEST | Press release
Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Araris Biotech AG (“Araris”) today announced that the U.S. Food and Drug Administration (FDA) has completed its Investigational New Drug (IND) review period for ARC-02, an antibody-drug conjugate (ADC) being developed for the treatment of non-Hodgkin lymphoma, enabling Taiho Oncology to initiate a Phase 1 dose-escalation clinical trial of ARC-02. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427127507/en/ Taiho Pharmaceutical acquired Araris Biotech in March 2025, expanding Taiho group’s capabilities in biologics and ADC research and development. Araris is a spin-off of the Paul Scherrer Institute and ETH in Switzerland focused on the development of antibody-drug conjugates (ADCs). Central to Araris’ approach is its proprietary AraLinQ™ ADC technology, which enables the creation of stable and site-specific ADCs using standard antibodies with scalable manufacturing
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
